1. Dzialas, V, Hoenig, MC, Prange, S, Bischof, GN, Parkinson’s Progression Marker Initiative, Drzezga, A et al.. Structural underpinnings and long-term effects of resilience in Parkinson's disease. NPJ Parkinsons Dis. 2024;10 (1):94. doi: 10.1038/s41531-024-00699-x. PubMed PMID:38697984 PubMed Central PMC11066097.
  2. Bischof, GN, Jaeger, E, Giehl, K, Jessen, F, Onur, OA, O'Bryant, S et al.. Cortical Tau Aggregation Patterns associated with Apraxia in Alzheimer's Disease. medRxiv. 2024; :. doi: 10.1101/2024.04.09.24305535. PubMed PMID:38645131 PubMed Central PMC11030486.
  3. Bischof, GN, Brendel, M, Barthel, H, Theis, H, Barbe, M, Bartenstein, P et al.. Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [F]PI-2620. J Nucl Med. 2024; :. doi: 10.2967/jnumed.123.265930. PubMed PMID:38575191 .
  4. Langerscheidt, F, Wied, T, Al Kabbani, MA, van Eimeren, T, Wunderlich, G, Zempel, H et al.. Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease-like TAU pathology in primary and secondary tauopathies. J Neurol. 2024; :. doi: 10.1007/s00415-024-12314-3. PubMed PMID:38554150 .
  5. Oltra, J, Segura, B, Strafella, AP, van Eimeren, T, Ibarretxe-Bilbao, N, Diez-Cirarda, M et al.. A multi-site study on sex differences in cortical thickness in non-demented Parkinson's disease. NPJ Parkinsons Dis. 2024;10 (1):69. doi: 10.1038/s41531-024-00686-2. PubMed PMID:38521776 PubMed Central PMC10960793.
  6. Jaeger, E, Bischof, GN, Onur, OA, Schlamann, M, Drzezga, A. Tau aggregation following subcortical hemorrhage. Eur J Nucl Med Mol Imaging. 2024; :. doi: 10.1007/s00259-024-06662-5. PubMed PMID:38433149 .
  7. Hönig, M, Altomare, D, Caprioglio, C, Collij, L, Barkhof, F, Van Berckel, B et al.. Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer Disease. Neurology. 2024;102 (6):e208053. doi: 10.1212/WNL.0000000000208053. PubMed PMID:38377442 PubMed Central PMC11033981.
  8. Theis, H, Pavese, N, Rektorová, I, van Eimeren, T. Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson's Disease. J Parkinsons Dis. 2024; :. doi: 10.3233/JPD-230385. PubMed PMID:38339941 .
  9. Giehl, K, Theis, H, Ophey, A, Hammes, J, Reker, P, Eggers, C et al.. Working Memory Training Responsiveness in Parkinson's Disease Is Not Determined by Cortical Thickness or White Matter Lesions. J Parkinsons Dis. 2024;14 (2):347-351. doi: 10.3233/JPD-230367. PubMed PMID:38277302 PubMed Central PMC10977422.
  10. Bischof, GN, Jaeger, E, Giehl, K, Hönig, MC, Alzheimer’s Disease Neuroimaging Initiative, Weiss, PH et al.. Affection of Motor Network Regions by Tau Pathology Across the Alzheimer's Disease Spectrum. eNeuro. 2024;11 (1):. doi: 10.1523/ENEURO.0242-23.2023. PubMed PMID:38164539 PubMed Central PMC10849022.
  11. Doering, E, Antonopoulos, G, Hoenig, M, van Eimeren, T, Daamen, M, Boecker, H et al.. MRI or F-FDG PET for Brain Age Gap Estimation: Links to Cognition, Pathology, and Alzheimer Disease Progression. J Nucl Med. 2024;65 (1):147-155. doi: 10.2967/jnumed.123.265931. PubMed PMID:38050112 PubMed Central PMC10755522.
  12. Theis, H, Prange, S, Bischof, GN, Hoenig, MC, Tittgemeyer, M, Timmermann, L et al.. Impulsive-compulsive behaviour in early Parkinson's disease is determined by apathy and dopamine receptor D3 polymorphism. NPJ Parkinsons Dis. 2023;9 (1):154. doi: 10.1038/s41531-023-00596-9. PubMed PMID:37968562 PubMed Central PMC10651866.
  13. Theis, H, Bischof, GN, Brüggemann, N, Dargvainiene, J, Drzezga, A, Grüter, T et al.. In Vivo Measurement of Tau Depositions in Anti-IgLON5 Disease Using [18F]PI-2620 PET. Neurology. 2023;101 (22):e2325-e2330. doi: 10.1212/WNL.0000000000207870. PubMed PMID:37879939 PubMed Central PMC10727210.
  14. Hoenig, MC, Dzialas, V, Banwinkler, M, Asendorf, A, Drzezga, A, van Eimeren, T et al.. Educational level and its association with dopamine transporter loss in patients with Parkinson's disease. Parkinsonism Relat Disord. 2023;115 :105844. doi: 10.1016/j.parkreldis.2023.105844. PubMed PMID:37690218 .
  15. Chakroun, K, Wiehler, A, Wagner, B, Mathar, D, Ganzer, F, van Eimeren, T et al.. Dopamine regulates decision thresholds in human reinforcement learning in males. Nat Commun. 2023;14 (1):5369. doi: 10.1038/s41467-023-41130-y. PubMed PMID:37666865 PubMed Central PMC10477234.
  16. van Eimeren, T, Giehl, K, Reetz, K, Sampaio, C, Mestre, TA. Neuroimaging biomarkers in Huntington's disease: Preparing for a new era of therapeutic development. Parkinsonism Relat Disord. 2023;114 :105488. doi: 10.1016/j.parkreldis.2023.105488. PubMed PMID:37407343 .
  17. Altomare, D, Barkhof, F, Caprioglio, C, Collij, LE, Scheltens, P, Lopes Alves, I et al.. Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial. JAMA Neurol. 2023;80 (6):548-557. doi: 10.1001/jamaneurol.2023.0997. PubMed PMID:37155177 PubMed Central PMC10167601.
  18. Schröter, N, van Eimeren, T, Classen, J, Levin, J, Redecker, C, Wolz, M et al.. Significance of clinical symptoms and red flags in early differential diagnosis of Parkinson's disease and atypical Parkinsonian syndromes. J Neural Transm (Vienna). 2023;130 (6):839-846. doi: 10.1007/s00702-023-02634-5. PubMed PMID:37046147 PubMed Central PMC10199882.
  19. Maier, F, Greuel, A, Hoock, M, Kaur, R, Tahmasian, M, Schwartz, F et al.. Impaired self-awareness of cognitive deficits in Parkinson's disease relates to cingulate cortex dysfunction. Psychol Med. 2023;53 (4):1244-1253. doi: 10.1017/S0033291721002725. PubMed PMID:37010224 PubMed Central PMC10009405.
  20. Caprioglio, C, Ribaldi, F, Visser, LNC, Minguillon, C, Collij, LE, Grau-Rivera, O et al.. Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline. JAMA Netw Open. 2023;6 (1):e2250921. doi: 10.1001/jamanetworkopen.2022.50921. PubMed PMID:36637820 PubMed Central PMC9857261.
  21. Madlener, M, Breuninger, M, Meißner, A, Stetefeld, H, Telentschak, S, Wille, T et al.. Brain abscess with Ureaplasma parvum in a patient with granulomatosis with polyangiitis. Infection. 2023;51 (3):779-782. doi: 10.1007/s15010-022-01966-w. PubMed PMID:36580229 PubMed Central PMC10205844.
  22. Hoenig, MC, Dzialas, V, Drzezga, A, van Eimeren, T. The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?. Mov Disord. 2023;38 (1):16-20. doi: 10.1002/mds.29266. PubMed PMID:36345092 .
  23. Banwinkler, M, Theis, H, Prange, S, van Eimeren, T. Imaging the Limbic System in Parkinson's Disease-A Review of Limbic Pathology and Clinical Symptoms. Brain Sci. 2022;12 (9):. doi: 10.3390/brainsci12091248. PubMed PMID:36138984 PubMed Central PMC9496800.
  24. Prange, S, Theis, H, Banwinkler, M, van Eimeren, T. Molecular Imaging in Parkinsonian Disorders-What's New and Hot?. Brain Sci. 2022;12 (9):. doi: 10.3390/brainsci12091146. PubMed PMID:36138882 PubMed Central PMC9496752.
  25. Ophey, A, Wenzel, J, Paul, R, Giehl, K, Rehberg, S, Eggers, C et al.. Cognitive Performance and Learning Parameters Predict Response to Working Memory Training in Parkinson's Disease. J Parkinsons Dis. 2022;12 (7):2235-2247. doi: 10.3233/JPD-223448. PubMed PMID:36120792 PubMed Central PMC9661332.
  26. Katzdobler, S, Nitschmann, A, Barthel, H, Bischof, G, Beyer, L, Marek, K et al.. Additive value of [F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome. Eur J Nucl Med Mol Imaging. 2023;50 (2):423-434. doi: 10.1007/s00259-022-05964-w. PubMed PMID:36102964 PubMed Central PMC9816230.
  27. Banwinkler, M, Dzialas, V, Parkinson's Progression Markers Initiative, Hoenig, MC, van Eimeren, T. Gray Matter Volume Loss in Proposed Brain-First and Body-First Parkinson's Disease Subtypes. Mov Disord. 2022;37 (10):2066-2074. doi: 10.1002/mds.29172. PubMed PMID:35943058 .
  28. Doering, E, Hoenig, MC, Bischof, GN, Bohn, KP, Ellingsen, LM, van Eimeren, T et al.. Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2022;49 (13):4478-4489. doi: 10.1007/s00259-022-05879-6. PubMed PMID:35831715 PubMed Central PMC9605923.
  29. Theis, H, Probst, C, Campabadal, A, Goerlich, KS, Granert, O, Wolff, S et al.. Inhibitory framing in hypersexual patients with Parkinson's disease. An fMRI pilot study. Exp Brain Res. 2022;240 (7-8):2097-2107. doi: 10.1007/s00221-022-06397-5. PubMed PMID:35763033 PubMed Central PMC9288360.
  30. Steidel, K, Ruppert, MC, Greuel, A, Tahmasian, M, Maier, F, Hammes, J et al.. Longitudinal trimodal imaging of midbrain-associated network degeneration in Parkinson's disease. NPJ Parkinsons Dis. 2022;8 (1):79. doi: 10.1038/s41531-022-00341-8. PubMed PMID:35732679 PubMed Central PMC9218128.
  31. C Monte-Rubio, G, Segura, B, P Strafella, A, van Eimeren, T, Ibarretxe-Bilbao, N, Diez-Cirarda, M et al.. Parameters from site classification to harmonize MRI clinical studies: Application to a multi-site Parkinson's disease dataset. Hum Brain Mapp. 2022;43 (10):3130-3142. doi: 10.1002/hbm.25838. PubMed PMID:35305545 PubMed Central PMC9188966.
  32. Hoenig, MC, Drzezga, A. Clear-headed into old age: Resilience and resistance against brain aging-A PET imaging perspective. J Neurochem. 2023;164 (3):325-345. doi: 10.1111/jnc.15598. PubMed PMID:35226362 .
  33. Peralta, C, Strafella, AP, van Eimeren, T, Ceravolo, R, Seppi, K, Kaasinen, V et al.. Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms. Mov Disord Clin Pract. 2022;9 (1):6-19. doi: 10.1002/mdc3.13354. PubMed PMID:35005060 PubMed Central PMC8721825.
  34. Schneider, CA, Täger, P, Hammes, J, Fischer, T, Drzezga, A, Pfister, D et al.. Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer. Nuklearmedizin. 2022;61 (1):25-32. doi: 10.1055/a-1670-9500. PubMed PMID:34918333 .
  35. Steidel, K, Ruppert, MC, Palaghia, I, Greuel, A, Tahmasian, M, Maier, F et al.. Dopaminergic pathways and resting-state functional connectivity in Parkinson's disease with freezing of gait. Neuroimage Clin. 2021;32 :102899. doi: 10.1016/j.nicl.2021.102899. PubMed PMID:34911202 PubMed Central PMC8645514.
  36. Draganova, R, Konietschke, F, Steiner, KM, Elangovan, N, Gümüs, M, Göricke, SM et al.. Motor training-related brain reorganization in patients with cerebellar degeneration. Hum Brain Mapp. 2022;43 (5):1611-1629. doi: 10.1002/hbm.25746. PubMed PMID:34894171 PubMed Central PMC8886660.
  37. Theis, H, Probst, C, Fernagut, PO, van Eimeren, T. Unlucky punches: the vulnerability-stress model for the development of impulse control disorders in Parkinson's disease. NPJ Parkinsons Dis. 2021;7 (1):112. doi: 10.1038/s41531-021-00253-z. PubMed PMID:34880241 PubMed Central PMC8654901.
  38. Tang, H, van Eimeren, T, Sampaio, C, Mestre, TA. Validation of biomarkers in Huntington disease to support the development of disease-modifying therapies: A systematic review and critical appraisal scheme. Parkinsonism Relat Disord. 2021;93 :89-96. doi: 10.1016/j.parkreldis.2021.10.013. PubMed PMID:34864305 .
  39. Khodadadifar, T, Soltaninejad, Z, Ebneabbasi, A, Eickhoff, CR, Sorg, C, Van Eimeren, T et al.. In search of convergent regional brain abnormality in cognitive emotion regulation: A transdiagnostic neuroimaging meta-analysis. Hum Brain Mapp. 2022;43 (4):1309-1325. doi: 10.1002/hbm.25722. PubMed PMID:34826162 PubMed Central PMC8837597.
  40. Zeuner, KE, Knutzen, A, Granert, O, Trampenau, L, Baumann, A, Wolff, S et al.. Never too little: Grip and lift forces following probabilistic weight cues in patients with writer's cramp. Clin Neurophysiol. 2021;132 (12):2937-2947. doi: 10.1016/j.clinph.2021.09.010. PubMed PMID:34715418 .
  41. Boccardi, M, Dodich, A, Albanese, E, Gayet-Ageron, A, Festari, C, Ashton, NJ et al.. Correction to: The Strategic Biomarker Roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. Eur J Nucl Med Mol Imaging. 2021;48 (13):4525-4531. doi: 10.1007/s00259-021-05549-z. PubMed PMID:34546388 PubMed Central PMC9172693.
  42. Ring, P, Keil, J, Muthuraman, M, Wolff, S, Bergmann, TO, Probst, C et al.. Oscillatory brain activity associated with skin conductance responses in the context of risk. J Neurophysiol. 2021;126 (3):924-933. doi: 10.1152/jn.00014.2021. PubMed PMID:34346697 .
  43. Pfeil, J, Hoenig, MC, Doering, E, van Eimeren, T, Drzezga, A, Bischof, GN et al.. Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease. Neurobiol Aging. 2021;106 :119-129. doi: 10.1016/j.neurobiolaging.2021.06.014. PubMed PMID:34284259 PubMed Central PMC8461082.
  44. Ring, P, Probst, CC, Neyse, L, Wolff, S, Kaernbach, C, van Eimeren, T et al.. Discounting Behavior in Problem Gambling. J Gambl Stud. 2022;38 (2):529-543. doi: 10.1007/s10899-021-10054-x. PubMed PMID:34268669 PubMed Central PMC9119884.
  45. Jergas, H, Grindegård, L, Schultze, T, Thanarajah, SE, Kalbe, E, van Eimeren, T et al.. The impact of subthalamic deep brain stimulation on belief revision and social validation. Parkinsonism Relat Disord. 2021;89 :84-86. doi: 10.1016/j.parkreldis.2021.06.020. PubMed PMID:34256332 .
  46. Song, M, Beyer, L, Kaiser, L, Barthel, H, van Eimeren, T, Marek, K et al.. Binding characteristics of [F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. J Cereb Blood Flow Metab. 2021;41 (11):2957-2972. doi: 10.1177/0271678X211018904. PubMed PMID:34044665 PubMed Central PMC8545042.
  47. Song, M, Scheifele, M, Barthel, H, van Eimeren, T, Beyer, L, Marek, K et al.. Feasibility of short imaging protocols for [F]PI-2620 tau-PET in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging. 2021;48 (12):3872-3885. doi: 10.1007/s00259-021-05391-3. PubMed PMID:34021393 PubMed Central PMC8484138.
  48. Schedlich-Teufer, C, Jost, ST, Krack, P, Witt, K, Weintraub, D, Baldermann, JC et al.. Assessment of Affective-Behavioral States in Parkinson's Disease Patients: Towards a New Screening Tool. J Parkinsons Dis. 2021;11 (3):1417-1430. doi: 10.3233/JPD-202375. PubMed PMID:33967055 .
  49. Palleis, C, Brendel, M, Finze, A, Weidinger, E, Bötzel, K, Danek, A et al.. Cortical [ F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. Mov Disord. 2021;36 (9):2104-2115. doi: 10.1002/mds.28624. PubMed PMID:33951244 .
  50. Bischof, GN, Bartenstein, P, Barthel, H, van Berckel, B, Doré, V, van Eimeren, T et al.. Toward a Universal Readout for F-Labeled Amyloid Tracers: The CAPTAINs Study. J Nucl Med. 2021;62 (7):999-1005. doi: 10.2967/jnumed.120.250290. PubMed PMID:33712532 .
  51. Boccardi, M, Dodich, A, Albanese, E, Gayet-Ageron, A, Festari, C, Ashton, NJ et al.. The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. Eur J Nucl Med Mol Imaging. 2021;48 (7):2070-2085. doi: 10.1007/s00259-020-05120-2. PubMed PMID:33688996 PubMed Central PMC8175304.
  52. Schaible, F, Maier, F, Buchwitz, TM, Schwartz, F, Hoock, M, Schönau, E et al.. Effects of Lee Silverman Voice Treatment BIG and conventional physiotherapy on non-motor and motor symptoms in Parkinson's disease: a randomized controlled study comparing three exercise models. Ther Adv Neurol Disord. 2021;14 :1756286420986744. doi: 10.1177/1756286420986744. PubMed PMID:33680093 PubMed Central PMC7897809.
  53. Ruppert, MC, Greuel, A, Freigang, J, Tahmasian, M, Maier, F, Hammes, J et al.. The default mode network and cognition in Parkinson's disease: A multimodal resting-state network approach. Hum Brain Mapp. 2021;42 (8):2623-2641. doi: 10.1002/hbm.25393. PubMed PMID:33638213 PubMed Central PMC8090788.
  54. Bischof, GN, Dodich, A, Boccardi, M, van Eimeren, T, Festari, C, Barthel, H et al.. Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging. 2021;48 (7):2110-2120. doi: 10.1007/s00259-020-05156-4. PubMed PMID:33590274 PubMed Central PMC8175320.
  55. Seemiller, J, Bischof, GN, Hoenig, MC, Tahmasian, M, van Eimeren, T, Drzezga, A et al.. Indication of retrograde tau spreading along Braak stages and functional connectivity pathways. Eur J Nucl Med Mol Imaging. 2021;48 (7):2272-2282. doi: 10.1007/s00259-020-05183-1. PubMed PMID:33462630 PubMed Central PMC8178161.
  56. Ophey, A, Rehberg, S, Giehl, K, Eggers, C, Reker, P, van Eimeren, T et al.. Predicting Working Memory Training Responsiveness in Parkinson's Disease: Both "System Hardware" and Room for Improvement Are Needed. Neurorehabil Neural Repair. 2021;35 (2):117-130. doi: 10.1177/1545968320981956. PubMed PMID:33410387 .
  57. Weller, A, Bischof, GN, Schlüter, P, Richter, N, Dronse, J, Onur, O et al.. Finding New Communities: A Principle of Neuronal Network Reorganization in Alzheimer's Disease. Brain Connect. 2021;11 (3):225-238. doi: 10.1089/brain.2020.0889. PubMed PMID:33356820 .
  58. Hoenig, MC, Willscheid, N, Bischof, GN, van Eimeren, T, Drzezga, A, Alzheimer’s Disease Neuroimaging Initiative et al.. Assessment of Tau Tangles and Amyloid-β Plaques Among Super Agers Using PET Imaging. JAMA Netw Open. 2020;3 (12):e2028337. doi: 10.1001/jamanetworkopen.2020.28337. PubMed PMID:33306113 PubMed Central PMC7733158.
  59. Brendel, M, Barthel, H, van Eimeren, T, Marek, K, Beyer, L, Song, M et al.. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol. 2020;77 (11):1408-1419. doi: 10.1001/jamaneurol.2020.2526. PubMed PMID:33165511 PubMed Central PMC7341407.
  60. Richter, N, Bischof, GN, Dronse, J, Nellessen, N, Neumaier, B, Langen, KJ et al.. Entorhinal Tau Predicts Hippocampal Activation and Memory Deficits in Alzheimer's Disease. J Alzheimers Dis. 2020;78 (4):1601-1614. doi: 10.3233/JAD-200835. PubMed PMID:33164934 .
  61. van Eimeren, T, Claßen, J, Drzezga, A, Eggers, C, Hilker-Roggendorf, R, Klucken, J et al.. [Recommendation for the differentiated use of nuclear medical diagnostic for parkinsonian syndromes]. Fortschr Neurol Psychiatr. 2020;88 (9):609-619. doi: 10.1055/a-1207-0515. PubMed PMID:32957144 .
  62. Giehl, K, Ophey, A, Hammes, J, Rehberg, S, Lichtenstein, T, Reker, P et al.. Working memory training increases neural efficiency in Parkinson's disease: a randomized controlled trial. Brain Commun. 2020;2 (2):fcaa115. doi: 10.1093/braincomms/fcaa115. PubMed PMID:32954349 PubMed Central PMC7472906.
  63. Hammes, J, Bischof, GN, Bohn, KP, Onur, Ö, Schneider, A, Fliessbach, K et al.. One-Stop Shop: F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases. J Nucl Med. 2021;62 (2):240-246. doi: 10.2967/jnumed.120.244061. PubMed PMID:32620704 .
  64. van Eimeren, T. Central autonomic dysfunction in multiple system atrophy: can we measure it with MRI?. Clin Auton Res. 2020;30 (3):185-187. doi: 10.1007/s10286-020-00695-0. PubMed PMID:32418031 PubMed Central PMC7250800.
  65. Beyer, L, Nitschmann, A, Barthel, H, van Eimeren, T, Unterrainer, M, Sauerbeck, J et al.. Early-phase [F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. Eur J Nucl Med Mol Imaging. 2020;47 (12):2911-2922. doi: 10.1007/s00259-020-04788-w. PubMed PMID:32318783 PubMed Central PMC7567714.
  66. Ophey, A, Giehl, K, Rehberg, S, Eggers, C, Reker, P, van Eimeren, T et al.. Effects of working memory training in patients with Parkinson's disease without cognitive impairment: A randomized controlled trial. Parkinsonism Relat Disord. 2020;72 :13-22. doi: 10.1016/j.parkreldis.2020.02.002. PubMed PMID:32078917 .
  67. Ruppert, MC, Greuel, A, Tahmasian, M, Schwartz, F, Stürmer, S, Maier, F et al.. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction. Brain. 2020;143 (3):944-959. doi: 10.1093/brain/awaa019. PubMed PMID:32057084 .
  68. Giehl, K, Ophey, A, Reker, P, Rehberg, S, Hammes, J, Barbe, MT et al.. Effects of Home-Based Working Memory Training on Visuo-Spatial Working Memory in Parkinson's Disease: A Randomized Controlled Trial. J Cent Nerv Syst Dis. 2020;12 :1179573519899469. doi: 10.1177/1179573519899469. PubMed PMID:32002011 PubMed Central PMC6966247.
  69. van Eimeren, T, Drzezga, A. From molecules to system failure: translational frontiers of multimodal imaging in neurodegenerative diseases. Eur J Nucl Med Mol Imaging. 2019;46 (13):2816-2818. doi: 10.1007/s00259-019-04562-7. PubMed PMID:31667539 .
  70. Dietlein, F, Kobe, C, Hohberg, M, Zlatopolskiy, BD, Krapf, P, Endepols, H et al.. Intraindividual Comparison of F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer. J Nucl Med. 2020;61 (5):729-734. doi: 10.2967/jnumed.119.234898. PubMed PMID:31628219 .
  71. Respondek, G, Grimm, MJ, Piot, I, Arzberger, T, Compta, Y, Englund, E et al.. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. Mov Disord. 2020;35 (1):171-176. doi: 10.1002/mds.27872. PubMed PMID:31571273 PubMed Central PMC7993399.
  72. Baldermann, JC, Bohn, KP, Hammes, J, Schüller, CB, Visser-Vandewalle, V, Drzezga, A et al.. Local and Global Changes in Brain Metabolism during Deep Brain Stimulation for Obsessive-Compulsive Disorder. Brain Sci. 2019;9 (9):. doi: 10.3390/brainsci9090220. PubMed PMID:31480355 PubMed Central PMC6770477.
  73. Hohberg, M, Kobe, C, Krapf, P, Täger, P, Hammes, J, Dietlein, F et al.. Biodistribution and radiation dosimetry of [F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer. EJNMMI Res. 2019;9 (1):66. doi: 10.1186/s13550-019-0540-7. PubMed PMID:31346821 PubMed Central PMC6658635.
  74. Sehlin, D, Syvänen, S, MINC faculty. Engineered antibodies: new possibilities for brain PET?. Eur J Nucl Med Mol Imaging. 2019;46 (13):2848-2858. doi: 10.1007/s00259-019-04426-0. PubMed PMID:31342134 PubMed Central PMC6879437.
  75. Dietlein, F, Hohberg, M, Kobe, C, Zlatopolskiy, BD, Krapf, P, Endepols, H et al.. An F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with F-JK-PSMA-7 During the First Year of Application. J Nucl Med. 2020;61 (2):202-209. doi: 10.2967/jnumed.119.229542. PubMed PMID:31324713 .
  76. Bischof, GN, Ewers, M, Franzmeier, N, Grothe, MJ, Hoenig, M, Kocagoncu, E et al.. Connectomics and molecular imaging in neurodegeneration. Eur J Nucl Med Mol Imaging. 2019;46 (13):2819-2830. doi: 10.1007/s00259-019-04394-5. PubMed PMID:31292699 PubMed Central PMC7613672.
  77. Riederer, P, Berg, D, Casadei, N, Cheng, F, Classen, J, Dresel, C et al.. α-Synuclein in Parkinson's disease: causal or bystander?. J Neural Transm (Vienna). 2019;126 (7):815-840. doi: 10.1007/s00702-019-02025-9. PubMed PMID:31240402 .
  78. Hoenig, MC, Bischof, GN, Onur, ÖA, Kukolja, J, Jessen, F, Fliessbach, K et al.. Level of education mitigates the impact of tau pathology on neuronal function. Eur J Nucl Med Mol Imaging. 2019;46 (9):1787-1795. doi: 10.1007/s00259-019-04342-3. PubMed PMID:31183635 .
  79. Trampenau, L, Kuhtz-Buschbeck, JP, van Eimeren, T. Parkinsonian patients do not utilize probabilistic advance information in a grip-lift task. Parkinsonism Relat Disord. 2019;65 :67-72. doi: 10.1016/j.parkreldis.2019.05.015. PubMed PMID:31105014 .
  80. van Eimeren, T, Antonini, A, Berg, D, Bohnen, N, Ceravolo, R, Drzezga, A et al.. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimers Dement (Amst). 2019;11 :301-309. doi: 10.1016/j.dadm.2019.01.011. PubMed PMID:30984816 PubMed Central PMC6446052.
  81. Yilmaz, R, Hopfner, F, van Eimeren, T, Berg, D. Biomarkers of Parkinson's disease: 20 years later. J Neural Transm (Vienna). 2019;126 (7):803-813. doi: 10.1007/s00702-019-02001-3. PubMed PMID:30949837 .
  82. Grimm, MJ, Respondek, G, Stamelou, M, Arzberger, T, Ferguson, L, Gelpi, E et al.. How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Mov Disord. 2019;34 (8):1228-1232. doi: 10.1002/mds.27666. PubMed PMID:30884545 PubMed Central PMC6699888.
  83. Giehl, K, Tahmasian, M, Eickhoff, SB, van Eimeren, T. Imaging executive functions in Parkinson's disease: An activation likelihood estimation meta-analysis. Parkinsonism Relat Disord. 2019;63 :137-142. doi: 10.1016/j.parkreldis.2019.02.015. PubMed PMID:30833230 .
  84. Hammes, J, Theis, H, Giehl, K, Hoenig, MC, Greuel, A, Tittgemeyer, M et al.. Dopamine metabolism of the nucleus accumbens and fronto-striatal connectivity modulate impulse control. Brain. 2019;142 (3):733-743. doi: 10.1093/brain/awz007. PubMed PMID:30753324 .
  85. Strafella, AP, Bohnen, NI, Pavese, N, Vaillancourt, DE, van Eimeren, T, Politis, M et al.. Imaging Markers of Progression in Parkinson's Disease. Mov Disord Clin Pract. 2018;5 (6):586-596. doi: 10.1002/mdc3.12673. PubMed PMID:30637278 PubMed Central PMC6277366.
  86. Hammes, J, Hohberg, M, Täger, P, Wild, M, Zlatopolskiy, B, Krapf, P et al.. Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CT. PLoS One. 2018;13 (12):e0209613. doi: 10.1371/journal.pone.0209613. PubMed PMID:30571794 PubMed Central PMC6301686.
  87. Hammes, J, van Heek, L, Hohberg, M, Reifegerst, M, Stockter, S, Dietlein, M et al.. Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases. EJNMMI Phys. 2018;5 (1):32. doi: 10.1186/s40658-018-0231-x. PubMed PMID:30539323 PubMed Central PMC6289932.
  88. Baumann, A, Nebel, A, Granert, O, Giehl, K, Wolff, S, Schmidt, W et al.. Neural Correlates of Hypokinetic Dysarthria and Mechanisms of Effective Voice Treatment in Parkinson Disease. Neurorehabil Neural Repair. 2018;32 (12):1055-1066. doi: 10.1177/1545968318812726. PubMed PMID:30444176 .
  89. Hammes, J, Drzezga, A, van Eimeren, T. The Role of Tau Imaging in Parkinsonian Disorders. Curr Neurol Neurosci Rep. 2018;18 (12):86. doi: 10.1007/s11910-018-0898-3. PubMed PMID:30293094 .
  90. Dodel, R, Koschel, J, Lorenzl, S, Levin, J, van Eimeren, T, Höglinger, G et al.. [Dementia with Lewy bodies]. Fortschr Neurol Psychiatr. 2018;86 (S 01):S43-S47. doi: 10.1055/a-0696-6249. PubMed PMID:30241100 .
  91. Kovacs, GG, Respondek, G, van Eimeren, T, Höller, E, Levin, J, Müller, U et al.. [Tauopathies : From molecule to therapy]. Nervenarzt. 2018;89 (10):1083-1094. doi: 10.1007/s00115-018-0584-3. PubMed PMID:30120488 .
  92. Hohberg, M, Kobe, C, Täger, P, Hammes, J, Schmidt, M, Dietlein, F et al.. Combined Early and Late [Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels. Mol Imaging Biol. 2019;21 (3):558-566. doi: 10.1007/s11307-018-1263-2. PubMed PMID:30105521 .
  93. Chong, TT, Apps, MAJ, Giehl, K, Hall, S, Clifton, CH, Husain, M et al.. Computational modelling reveals distinct patterns of cognitive and physical motivation in elite athletes. Sci Rep. 2018;8 (1):11888. doi: 10.1038/s41598-018-30220-3. PubMed PMID:30089782 PubMed Central PMC6082862.
  94. Ring, P, Probst, CC, Neyse, L, Wolff, S, Kaernbach, C, van Eimeren, T et al.. It's all about gains: Risk preferences in problem gambling. J Exp Psychol Gen. 2018;147 (8):1241-1255. doi: 10.1037/xge0000418. PubMed PMID:29878809 .
  95. Schweyer, K, Busche, MA, Hammes, J, Zwergal, A, Buhmann, C, van Eimeren, T et al.. Pearls & Oy-sters: Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy: Eyes up. Neurology. 2018;90 (10):482-485. doi: 10.1212/WNL.0000000000005069. PubMed PMID:29507134 .
  96. Schwartz, F, Tahmasian, M, Maier, F, Rochhausen, L, Schnorrenberg, KL, Samea, F et al.. Overlapping and distinct neural metabolic patterns related to impulsivity and hypomania in Parkinson's disease. Brain Imaging Behav. 2019;13 (1):241-254. doi: 10.1007/s11682-017-9812-x. PubMed PMID:29322397 .
  97. Hoenig, MC, Bischof, GN, Seemiller, J, Hammes, J, Kukolja, J, Onur, ÖA et al.. Networks of tau distribution in Alzheimer's disease. Brain. 2018;141 (2):568-581. doi: 10.1093/brain/awx353. PubMed PMID:29315361 .
  98. Hammes, J, Täger, P, Drzezga, A. EBONI: A Tool for Automated Quantification of Bone Metastasis Load in PSMA PET/CT. J Nucl Med. 2018;59 (7):1070-1075. doi: 10.2967/jnumed.117.203265. PubMed PMID:29242401 .
  99. Hammes, J, Leuwer, I, Bischof, GN, Drzezga, A, van Eimeren, T. Multimodal correlation of dynamic [F]-AV-1451 perfusion PET and neuronal hypometabolism in [F]-FDG PET. Eur J Nucl Med Mol Imaging. 2017;44 (13):2249-2256. doi: 10.1007/s00259-017-3840-z. PubMed PMID:29026951 .
  100. Hammes, J, Kobe, C, Hilgenberg, U, Lieb, WE, Drzezga, A. Orbital Hemangiopericytoma in 68Ga-Prostate-Specific Membrane Antigen-HBED-CC PET/CT. Clin Nucl Med. 2017;42 (10):812-814. doi: 10.1097/RLU.0000000000001791. PubMed PMID:28806257 .
  101. Hammes, J., Bischof, G.N. & Drzezga, A. Clin Transl Imaging (2017) 5: 465.
Search PubMed